Allianz Research Institute

09/28/2024

Exciting news.

The FDA today approved Dupilumab or Dupixent, first biologic to treat COPD, a disease that is third leading cause of death world wide and 6th in the USA. This will further reduce exacerbation rate for the treatment of COPD. It’s a game changer for those suffering from COPD or smoking related lung disease.

For those who participated in our Notus copd trial for dupilumab. Your participation has made this possible.

Thank you.

If you are interested In other trials, please reach out to us.

https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-us-first-ever-biologic-medicine?utm_campaign=regeneron+copd+fda&utm_source=linkedin&utm_medium=social

05/23/2024

We will start doing rsv testing as the cold and flu season starts up again

Contact us to learn more.

05/16/2024

For those who we’re immunocompromised patients volunteered for our Supernova covid prophylaxis monoclonal drug

Here the updated press release.

The drug helped prevent covid.

Once every 6 months.

Contacted us for other opportunities to volunteer in discovery great therapies for Asthma and COPD.

SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population PUBLISHED 16 May 2024 Positive high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial showed AstraZeneca’s...

12/22/2023

Game changer In COPD

Amazing steps moving forward for dupilumab or Dupixent - Sanofi/Regeneron for COPD.

Both Boreas and Notus trial show benefits of Dupixent in reducing COPD exacerbation and lung function.

To be involved in such cutting edge research - IM us.

https://www.sanofi.com/en/media-room/press-releases/2023/2023-11-27-06-30-00-2785836

https://www.nejm.org/doi/full/10.1056/NEJMoa2303951

Original Article from The New England Journal of Medicine — Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts